167 related articles for article (PubMed ID: 34280779)
1. A Computational Tumor-Infiltrating Lymphocyte Assessment Method Comparable with Visual Reporting Guidelines for Triple-Negative Breast Cancer.
Sun P; He J; Chao X; Chen K; Xu Y; Huang Q; Yun J; Li M; Luo R; Kuang J; Wang H; Li H; Hui H; Xu S
EBioMedicine; 2021 Aug; 70():103492. PubMed ID: 34280779
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
3. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract][Full Text] [Related]
4. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
5. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
[TBL] [Abstract][Full Text] [Related]
6. Why pathologists and oncologists should know about tumour-infiltrating lymphocytes (TILs) in triple-negative breast cancer: an Australian experience of 139 cases.
Fuchs TL; Pearson A; Pickett J; Diakos C; Dewar R; Chan D; Guminski A; Menzies A; Baron-Hay S; Sheen A; Sioson L; Chou A; Gill AJ
Pathology; 2020 Aug; 52(5):515-521. PubMed ID: 32553444
[TBL] [Abstract][Full Text] [Related]
7. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
8. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
13. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
Loi S; Michiels S; Salgado R; Sirtaine N; Jose V; Fumagalli D; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Desmedt C; Piccart MJ; Loibl S; Denkert C; Smyth MJ; Joensuu H; Sotiriou C
Ann Oncol; 2014 Aug; 25(8):1544-50. PubMed ID: 24608200
[TBL] [Abstract][Full Text] [Related]
14. Hotspot enumeration of CD8+ tumor-infiltrating lymphocytes using digital image analysis in triple-negative breast cancer yields consistent results.
McIntire PJ; Zhong E; Patel A; Khani F; D'Alfonso TM; Chen Z; Shin SJ; Ginter PS
Hum Pathol; 2019 Mar; 85():27-32. PubMed ID: 30381263
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes and CD8
Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
[TBL] [Abstract][Full Text] [Related]
16. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
Pinard C; Debled M; Ben Rejeb H; Velasco V; Tunon de Lara C; Hoppe S; Richard E; Brouste V; Bonnefoi H; MacGrogan G
Breast Cancer Res Treat; 2020 Jan; 179(1):11-23. PubMed ID: 31529299
[TBL] [Abstract][Full Text] [Related]
17. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
[TBL] [Abstract][Full Text] [Related]
18. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
19. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
[TBL] [Abstract][Full Text] [Related]
20. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
